The LVT DURATION (Optimal Duration of Anticoagulation for LV Thrombus) is a pilot study planned to assess the practicalities of conducting a randomised control trial (RCT) whilst establishing data around the ideal duration of anticoagulation in the treatment of LV thrombus. The main objectives of the study are:
* To assess the practicalities of conducting an RCT with regard to recruitment, retention, and outcome measurement. * To identify the optimal length of anticoagulation in the treatment of LV Thrombus
After randomisation participants will:
* Continue their prescribed oral anticoagulant for the remainder of the trial * Discontinue their prescribed oral anticoagulant for the remainder of the trial
Diagnosis of LV thrombus less than 12 months ago
On Apixaban at the time of randomisation
Completed at least 3 months of anticoagulation treatment for LV thrombus
Persistent laminar/ mural thrombus or persistent LV dysfunction
Any clinical condition requiring long term anticoagulation treatment as per investigator's judgement.
SSE since LV thrombus diagnosis
Contraindication to continuing anticoagulation therapy
Non-ischaemic Cardiomyopathy